

The Medical Letter[®]

on Drugs and Therapeutics

Volume 66

July 22, 2024

ISSUE No.
1707

IN THIS ISSUE

In Brief: *Wezlana* – An Ustekinumab Biosimilar Interchangeable with *Stelara*p 119

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 66 (Issue 1707)

July 22, 2024

[Take CME Exams](#)

IN BRIEF

Wezlana – An Ustekinumab Biosimilar Interchangeable with Stelara

The FDA has approved ustekinumab-auub (*Wezlana* – Amgen), an interchangeable biosimilar product similar to the interleukin-12 and -23 antagonist *Stelara*, for treatment of the same indications as *Stelara* (see Table 1). *Wezlana* is the first *Stelara* biosimilar to be approved in the US.

Pronunciation Key

Ustekinumab-auub: us" te kin' ue mab

Wezlana: wez lah' nah

The four-letter suffix -auub has no pronunciation or meaning; such suffixes are now added to biologic drugs to distinguish reference products from their biosimilars.

A biosimilar is a biologic product that is highly similar in composition, potency, and biologic properties to and has no clinically meaningful differences in safety, purity, and potency from the FDA-approved reference product. For a biosimilar to be approved as an interchangeable product, the manufacturer generally conducts clinical trials to prove that the results will be the same if the patient switches between the reference product and the biosimilar. In clinical studies, there were no clinically significant differences in efficacy and safety between *Wezlana* and *Stelara* for treatment of moderate to severe plaque psoriasis. The FDA extrapolated approval of *Wezlana* to psoriatic arthritis, Crohn's disease, and ulcerative colitis based on available data.¹⁻³

According to federal law, an interchangeable product can be substituted for the reference product by the pharmacist without permission from the prescriber. Some states require the pharmacist to notify

Table 1. FDA-Approved Indications of *Stelara* and *Wezlana*

- ▶ Treatment of moderate to severe plaque psoriasis in patients ≥ 6 years old who are candidates for phototherapy or systemic therapy
- ▶ Treatment of active psoriatic arthritis in patients ≥ 6 years old
- ▶ Treatment of moderately to severely active Crohn's disease in adults
- ▶ Treatment of moderately to severely active ulcerative colitis in adults

the prescriber and/or patient before making the substitution; currently four states (AL, IN, SC, and WA) restrict interchangeability entirely.⁴

Wezlana will be launched in early 2025 when *Stelara*'s patent exclusivity expires. The cost of the drug is not yet available, but will presumably be less expensive than *Stelara*. The wholesale acquisition cost (WAC) for a 12-week supply of *Stelara* for treatment of plaque psoriasis for a 75-kg patient is about \$13,300 and for treatment of Crohn's disease or ulcerative colitis is about \$26,500.⁵ ■

1. V Chow et al. Pharmacokinetic similarity of ABP 654, an ustekinumab biosimilar candidate: results from a randomized, double-blind study in healthy subjects. *Clin Pharmacol Drug Dev* 2023; 12:863.
2. G Cantin et al. Analytical and functional similarity of the biosimilar candidate ABP 654 to ustekinumab reference product. *Drugs R D* 2023; 23:421.
3. NIH. A study to investigate ABP 654 for the treatment of participants with moderate to severe plaque psoriasis. Available at: <https://clinicaltrials.gov/study/NCT04607980>. Accessed June 19, 2024.
4. S Humphreys. Understanding interchangeable biosimilars at the federal and state levels. *Am J Manag Care* 2023; 29:SP545.
5. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. June 5, 2024. Reprinted with permission by First Databank, Inc. All rights reserved. ©2024. www.fdbhealth.com/policies/drug-pricing-policy.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
3 years - \$398. \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected: 

Copyright 2024. ISSN 1523-2859

The
Medical
Letter